Ironwood Pharmaceuticals (NASDAQ:IRWD) Share Price Crosses Above Two Hundred Day Moving Average – Here’s Why

Shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) crossed above its 200-day moving average during trading on Thursday. The stock has a 200-day moving average of $3.97 and traded as high as $4.41. Ironwood Pharmaceuticals shares last traded at $4.03, with a volume of 4,985,414 shares traded.

Ironwood Pharmaceuticals News Roundup

Here are the key news stories impacting Ironwood Pharmaceuticals this week:

• Positive Sentiment: Ironwood reported Q3 adjusted earnings of $0.36 per share, above analyst expectations, while net income rose 49% year over year. It raised 2026 revenue guidance to $485 million–$510 million, above the roughly $470.5 million consensus, and increased its EBITDA outlook. Management also cited stronger Linzess sales expectations and profitability. Ironwood Q3 net income rises and outlook increases
• Neutral Sentiment: Revenue commentary was inconsistent: one Zacks headline described revenue as missing expectations, while reported figures of $133.04 million exceeded the estimate of $119.99 million cited elsewhere. Zacks Q3 earnings and outlook coverage

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on IRWD shares. Zacks Research lowered Ironwood Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 30th. Wall Street Zen raised Ironwood Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Saturday. Jefferies Financial Group upgraded Ironwood Pharmaceuticals to a “hold” rating in a research report on Friday, September 25th. Finally, Weiss Ratings upgraded Ironwood Pharmaceuticals from a “hold (c)” rating to a “hold (c+)” rating in a report on Thursday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $6.23.

Ironwood Pharmaceuticals Trading Up 8.9%

The stock’s 50-day moving average price is $3.91 and its 200-day moving average price is $3.97. The company has a market capitalization of $725.40 million, a P/E ratio of 4.88 and a beta of 0.25.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last announced its quarterly earnings data on Thursday, November 5th. The biotechnology company reported $0.36 earnings per share for the quarter, beating analysts’ consensus estimates of $0.32 by $0.04. The business had revenue of $133.04 million during the quarter, compared to the consensus estimate of $119.99 million. Ironwood Pharmaceuticals had a net margin of 33.36% and a negative return on equity of 58.38%. Sell-side analysts expect that Ironwood Pharmaceuticals, Inc. will post 1.10 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Ironwood Pharmaceuticals

Institutional investors have recently modified their holdings of the company. Arrowstreet Capital Limited Partnership increased its holdings in shares of Ironwood Pharmaceuticals by 724.5% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 3,397,242 shares of the biotechnology company’s stock worth $11,924,000 after acquiring an additional 2,985,181 shares during the period. Dimensional Fund Advisors LP grew its position in Ironwood Pharmaceuticals by 529.3% in the 1st quarter. Dimensional Fund Advisors LP now owns 2,082,055 shares of the biotechnology company’s stock worth $7,307,000 after purchasing an additional 1,751,219 shares during the last quarter. Hillsdale Investment Management Inc. grew its position in Ironwood Pharmaceuticals by 6.9% in the 1st quarter. Hillsdale Investment Management Inc. now owns 1,236,628 shares of the biotechnology company’s stock worth $4,341,000 after purchasing an additional 80,250 shares during the last quarter. Pacer Advisors Inc. bought a new position in Ironwood Pharmaceuticals in the 1st quarter worth about $3,982,000. Finally, Ritholtz Wealth Management increased its stake in shares of Ironwood Pharmaceuticals by 130.8% in the third quarter. Ritholtz Wealth Management now owns 831,091 shares of the biotechnology company’s stock valued at $3,299,000 after purchasing an additional 470,997 shares during the period.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc is a gastrointestinal-focused biopharmaceutical company headquartered in Boston, Massachusetts. The company discovers, develops, and commercializes medicines intended to treat disorders affecting the gastrointestinal tract, with an emphasis on conditions involving gut motility and visceral sensitivity.

Ironwood’s principal commercial product is Linzess (linaclotide), marketed in the United States in collaboration with AbbVie. Linzess is approved for adults with irritable bowel syndrome with constipation and chronic idiopathic constipation.